Guardant Health (GH) Projected to Post Quarterly Earnings on Thursday

Guardant Health (NASDAQ:GH) is expected to be announcing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect Guardant Health to post earnings of ($0.43) per share and revenue of $269.7380 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Guardant Health Trading Up 2.4%

GH opened at $107.58 on Thursday. The company has a market capitalization of $13.56 billion, a price-to-earnings ratio of -33.51 and a beta of 1.63. Guardant Health has a 12-month low of $34.88 and a 12-month high of $120.74. The business’s fifty day simple moving average is $106.44 and its 200-day simple moving average is $83.20.

Wall Street Analyst Weigh In

A number of research analysts have commented on GH shares. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research report on Wednesday, January 7th. Canaccord Genuity Group lifted their price objective on shares of Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Morgan Stanley upped their target price on Guardant Health from $105.00 to $130.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Stifel Nicolaus lifted their price target on Guardant Health from $100.00 to $120.00 and gave the company a “buy” rating in a report on Friday, January 9th. Finally, Mizuho set a $135.00 price objective on Guardant Health in a research note on Friday, January 9th. Twenty-one research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $106.86.

Insiders Place Their Bets

In related news, CTO Darya Chudova sold 5,451 shares of Guardant Health stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $104.04, for a total transaction of $567,122.04. Following the transaction, the chief technology officer owned 7,012 shares in the company, valued at approximately $729,528.48. This trade represents a 43.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the transaction, the chief executive officer directly owned 2,047,143 shares in the company, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 434,627 shares of company stock valued at $45,592,052. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Guardant Health

Institutional investors have recently modified their holdings of the company. Picton Mahoney Asset Management acquired a new position in shares of Guardant Health in the fourth quarter valued at approximately $16,243,000. Meeder Asset Management Inc. increased its position in shares of Guardant Health by 18,239.5% during the fourth quarter. Meeder Asset Management Inc. now owns 7,886 shares of the company’s stock worth $805,000 after acquiring an additional 7,843 shares during the period. Empowered Funds LLC raised its stake in shares of Guardant Health by 946.7% in the fourth quarter. Empowered Funds LLC now owns 71,879 shares of the company’s stock valued at $7,342,000 after acquiring an additional 65,012 shares in the last quarter. Illinois Municipal Retirement Fund purchased a new position in Guardant Health in the fourth quarter valued at $1,197,000. Finally, Janney Montgomery Scott LLC grew its stake in Guardant Health by 1.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 26,280 shares of the company’s stock worth $2,684,000 after purchasing an additional 444 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.